Shares of Dendreon (Nasdaq: DNDN) are trading significantly higher ... But how much room is left to run in the stock? …
Companies whose shares are expected to trade actively in today’s session are KBR, Inc. (NYSE:KBR), Dendreon Corporation (NASDAQ:DNDN), Best Buy Co., Inc. (NYSE ... DNDN): The biotech stock has been heavily shorted for …
The volatility of Dendreon's stock provides a fascinating insight into the allure of a new treatment modality, the bungles of the Provenge trials and the steely determination of the company to bring its first ever product to market. Dendreon's …
I talked to Greg Schiffman, Dendreon’s CFO, this morning on the company’s announcement that it would raise about $46 million, after fees, by selling some of its stock to an institutional investor. Below are some highlights of that interview.
Thus, I'm buying here. As per Dendreon (DNDN), the stock that lost 65% of it's value yesterday based on lower earnings guidance, I think it was well overdue. It had a $6B market cap based on no current earnings and one drug, Provenge, …
an investor, purporting to represent a class consisting of persons who purchased Dendreon common stock between April 29, 2010 and August 3, 2011, sought unspecified damages from Dendreon and three current and former officers of the …
That move prompted at least six brokerages to cut their rating on Dendreon s stock. The company has pointed to reimbursement concerns and delayed physician adoption as the primary reasons why Provenge s sales growth has …
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …
Friday it will pay for a greater number of patients to receive Provenge, a prostate cancer drug made by Dendreon Corp, sending Dendreon's shares up as much as 10 percent. Aetna will now provide coverage for patients with metastatic …
The plaintiff alleges that certain defendants knew the rosy statements were "completely false" and unlike defendants, …